Mesoblast Limited (MESO) 株式分析

企業概要

Mesoblast Limited is a biotechnology enterprise focused on the development of regenerative medicine products across Australia, the United States, Singapore, and Switzerland. The company leverages a proprietary technology platform built upon specialized cells known as mesenchymal lineage to advance its core business objectives. Operating within the Healthcare sector and the Biotechnology industry, Mesoblast targets markets characterized by high research and development intensity and long-term product development cycles. With a market capitalization of $1.90B, annual revenue of $65.38M, and an employee count of 81, the firm operates at a significant scale relative to its workforce size. The substantial market cap relative to its annual revenue indicates that the market places a high premium on the company's intellectual property and future potential, rather than current cash flow generation. This valuation structure is typical for biotechnology firms where the primary asset value lies in the pipeline of potential therapies rather than immediate profitability.

財務健全性

The company reported revenue of $65.38M over the trailing twelve months, yet posted a net income of -$94,370,000 and an EBITDA of -$64,339,000. The substantial disparity between the $65.38M revenue and the -$94.37M net income reveals an aggressive cost structure where operating expenses and cost of goods sold significantly exceed total sales. Additionally, the free cash flow stands at -$69,438,336, indicating that the company is currently burning cash rather than generating liquidity for operations or capital returns. This negative cash flow situation suggests limited financial flexibility for the current period, relying instead on external financing or existing reserves to fund ongoing research and development activities. The gross margin is recorded at -35.5%, while the operating margin sits at -55.2% and the profit margin is -144.3%, all reflecting the heavy investment costs inherent in the biotechnology sector before achieving product commercialization. On the balance sheet, total cash of $129.97M partially offsets total debt of $135.14M, resulting in a debt-to-equity ratio of 23.52, which indicates a leveraged position where debt obligations exceed cash reserves. The current ratio of 1.58 suggests that the company holds sufficient current assets to cover its short-term liabilities, maintaining a baseline of liquidity despite the net loss position. Return on Equity is -18.2% and Return on Assets is -6.2%, metrics that collectively indicate that management effectiveness in generating profit from shareholders' equity and total assets is currently negative due to the heavy investment phase of the business.

バリュエーション評価

The trailing P/E ratio is not available due to the net loss, while the forward P/E is listed as -161.67, a metric that implies earnings are currently negative and future expectations for profitability are not yet realized in traditional valuation terms. The price-to-book ratio stands at 32.62, indicating that the market values the company at more than 32 times its book value, which suggests a significant market premium assigned to its intangible assets and future revenue potential. Alternative valuation metrics such as the price-to-sales ratio of 29.12 and the EV/EBITDA of -291.47 further highlight that standard profitability-based multiples are not applicable, with the negative EV/EBITDA reflecting the company's lack of current earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $21.50 and a 52-week low of $9.66, and without the current specific price provided in the facts, the valuation context relies on these historical bounds to define the trading range. The beta value of 0.82 indicates that the stock's price volatility is slightly lower than the broader market, suggesting a relative stability compared to high-beta biotechnology peers during market fluctuations.

Growth & Income

Revenue growth over the year-over-year period reached an impressive 1526.8%, driven likely by significant cost reductions in research or specific commercial milestones, while earnings growth is not available due to the company's continued net losses. Since the earnings growth rate is not applicable, it is impossible to compare the pace of earnings expansion against revenue growth, but the massive revenue surge demonstrates rapid top-line expansion. Mesoblast Limited does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available capital back into its operations and research programs rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by aggressive top-line expansion funded by existing cash reserves and external capital, with no current income distribution to investors.